IRIS
CIGLIANO, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.717
AS - Asia 3.034
SA - Sud America 1.750
EU - Europa 1.424
Continente sconosciuto - Info sul continente non disponibili 116
AF - Africa 115
OC - Oceania 8
Totale 12.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.567
BR - Brasile 1.521
SG - Singapore 1.260
CN - Cina 732
UA - Ucraina 425
VN - Vietnam 312
HK - Hong Kong 284
IT - Italia 242
DE - Germania 218
FR - Francia 136
AR - Argentina 82
FI - Finlandia 81
GB - Regno Unito 75
SE - Svezia 70
CA - Canada 60
IN - India 57
BD - Bangladesh 56
IQ - Iraq 54
EC - Ecuador 43
ID - Indonesia 40
MX - Messico 39
TR - Turchia 38
RU - Federazione Russa 32
ZA - Sudafrica 28
MA - Marocco 26
UZ - Uzbekistan 26
PK - Pakistan 25
CO - Colombia 23
CZ - Repubblica Ceca 23
VE - Venezuela 23
BE - Belgio 20
JP - Giappone 20
KR - Corea 18
NL - Olanda 18
PY - Paraguay 18
PL - Polonia 17
AT - Austria 16
PE - Perù 15
CL - Cile 13
DZ - Algeria 13
KE - Kenya 13
ES - Italia 11
AE - Emirati Arabi Uniti 9
EG - Egitto 9
AU - Australia 8
AZ - Azerbaigian 8
DO - Repubblica Dominicana 8
IL - Israele 8
JM - Giamaica 8
JO - Giordania 8
TN - Tunisia 8
NP - Nepal 7
SA - Arabia Saudita 7
TT - Trinidad e Tobago 7
UY - Uruguay 7
CR - Costa Rica 6
EU - Europa 6
KZ - Kazakistan 6
LT - Lituania 6
OM - Oman 6
PA - Panama 6
PH - Filippine 6
BG - Bulgaria 5
HN - Honduras 5
IR - Iran 5
MY - Malesia 5
PS - Palestinian Territory 5
AM - Armenia 4
BO - Bolivia 4
BY - Bielorussia 4
GR - Grecia 4
KG - Kirghizistan 4
LB - Libano 4
NI - Nicaragua 4
RO - Romania 4
RS - Serbia 4
SN - Senegal 4
AL - Albania 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
GE - Georgia 3
IE - Irlanda 3
LK - Sri Lanka 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
MD - Moldavia 2
MU - Mauritius 2
PR - Porto Rico 2
SV - El Salvador 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
KH - Cambogia 1
Totale 12.045
Salva come PNG Salva come JPEG
Città #
Dallas 1.830
Singapore 694
Chandler 645
San Jose 369
Hong Kong 281
Ashburn 270
Jacksonville 226
Beijing 205
Princeton 184
Santa Clara 165
Council Bluffs 140
New York 127
Columbus 125
São Paulo 114
Nanjing 102
Ho Chi Minh City 100
Lauterbourg 95
Sassari 88
Ann Arbor 79
Hanoi 69
Wilmington 64
Los Angeles 63
Rio de Janeiro 56
Shanghai 50
Belo Horizonte 41
Dearborn 41
Boardman 40
Nanchang 36
Munich 30
Helsinki 27
Baghdad 26
Curitiba 25
Mountain View 25
Orem 25
Tashkent 25
The Dalles 24
Changsha 22
Houston 22
Shenyang 22
Woodbridge 22
Brasília 21
Tianjin 21
San Francisco 20
Toronto 20
Brussels 19
Buffalo 19
Denver 19
Atlanta 18
Brno 18
Campinas 18
Da Nang 18
Porto Alegre 18
Tokyo 18
Chennai 17
Guayaquil 17
Haiphong 17
Montreal 17
Seoul 17
Ribeirão Preto 16
Frankfurt am Main 15
Hebei 15
Andover 14
Boston 14
Jiaxing 14
Johannesburg 14
London 14
Quito 14
Salvador 14
Warsaw 14
Zhengzhou 14
Guarulhos 13
Nairobi 13
Norwalk 13
Rome 13
Fortaleza 12
Goiânia 12
Nuremberg 12
Santo André 12
Betim 11
Brooklyn 11
Dhaka 11
Jinan 11
Mexico City 11
Milan 11
Osasco 11
Cagliari 10
Juiz de Fora 10
Kunming 10
Manaus 10
Ningbo 10
Poplar 10
Recife 10
Seattle 10
Stockholm 10
Asunción 9
Blumenau 9
Bogotá 9
Campo Grande 9
Caxias do Sul 9
Guangzhou 9
Totale 7.419
Salva come PNG Salva come JPEG
Nome #
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 352
Design, synthesis and antileukemia evaluation of Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors 257
Design, synthesis and antileukemia evaluation of Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors 248
New Imatinib-like compounds as Bcr-Abl1 protein kinase inhibitors: design, synthesis and biological evaluation 214
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 201
A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. IF 2009: 4.522 JCR: Q1 198
Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. 197
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 191
Apolipoprotein Profiles in Atherosclerotic Disease 186
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 182
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras protooncogenes 180
Apolipoprotein profiles in atherosclerotic disease 177
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 175
Association between human plasma chondroitin sulphate isomers and carotid atherosclerotic plaque 168
Aortic and pulmonary bioprosthetic heart valves: an insight on glycosaminoglycan distribution and fine structure in decellularized porcine scaffolds for tissue engineering purposes 168
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver 165
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 163
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 161
Apolipoprotein Profiles in Atherosclerotic Disease 157
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 156
MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes 156
Apolipoprotein profiles in atherosclerotic disease 150
Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma 147
Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development 147
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 145
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans 145
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 144
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 141
Evaluation of plasma glycosaminoglycans levels and structure in patients undergoing carotid endarterectomy 138
Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma 137
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 137
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice 136
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype 134
Differential distribution of structural components and hydration in aortic and pulmonary heart valve conduits: Impact of detergent-based cell removal. IF 2010: 4.824 JCR: Q1 133
Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1 132
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 130
SNAI1 promotes the cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model 127
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans 127
Evaluation of plasma glycosaminoglycans levels and structure in patients undergoingcarotid endarterectomy 125
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma 123
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade 120
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma 117
Corrigendum to ‘TAZ is indispensable for c-MYC-induced hepatocarcinogenesis’ [J Hepatol (2022) 123–134] (Journal of Hepatology (2022) 76(1) (123–134), (S016882782102016X), (10.1016/j.jhep.2021.08.021)) 111
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma 110
PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. 109
Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis 108
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis 108
Pivotal role of fatty acid synthase in c-myc driven hepatocarcinogenesis 105
Structural analisys of plasma glycosaminoglycans in patients with atheromatous lesions 104
New Imatinib-like compounds as Bcr-Abl1 protein kinase inhibitors: design, synthesis and antileukemia evaluation 101
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease 101
Loss of pten synergizes with c-met to promote hepatocellular carcinoma development via mTORC2 pathway 101
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. 101
Erratum: Frizzled-10 extracellular vesicles plasma concentration is associated with tumoral progression in patients with colorectal and gastric cancer (Journal of Oncology (2019) 2019 (2715968) DOI: 10.1155/2019/2715968) 100
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 99
Glycosaminoglycan content and distribution in human normal and varicose veins 98
PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells 98
New Capillary Zone Electrophoresis (CZE) method for glycosaminoglycan analysis 97
TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma 96
The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans 96
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 96
Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase 95
Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles 93
Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. 93
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice 92
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. 91
Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression 91
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges 90
Glycosaminoglycan diversity in marine sponge extracellular matrix 90
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model 89
Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice 89
GLYCOSAMINOGLYCAN DIVERSITY IN MARINE SPONGE EXTRACELLULAR MATRIX 88
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 87
Role of the Notch signaling in cholangiocarcinoma 86
Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer 85
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma 84
Proteomic study of differential protein expression in stable and unstable human atherosclerotic plaque 83
Functional role of SGK3 in PI3K/Pten driven liver tumor development 82
Proteomic study of differential protein expression in stable and unstable human atherosclerotic plaque 82
Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair 82
Glycosaminoglycans and fabry’s disease 81
Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium 81
Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation 80
Ultrasensitive Capillary Zone Electrophoresis (CZE) for glycosaminoglycan analisys in normal human plasma 80
Human serum albumin Cys34 oxidative modifications after infiltration in the carotid atherosclerotic plaque 79
Molecular and metabolic changes in human clear cell liver foci 78
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 77
Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans 76
Structural analysis of glycosaminoglycans from fresh porcine aortic valves 75
Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. 75
TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives 75
Transcriptomic and Proteomic Analysis of Clear Cell Foci (CCF) in the Human Non-Cirrhotic Liver Identifies Several Differentially Expressed Genes and Proteins with Functions in Cancer Cell Biology and Glycogen Metabolism 74
Structural analysis of plasma glycosaminoglycans in patients undergoing carotid endarterectomy 73
Human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 72
Current challenges to underpinning the genetic basis for cholangiocarcinoma 72
eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma 71
Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice 71
Overexpression of SMAD7 activates the YAP/NOTCH cascade and promotes liver carcinogenesis in mice and humans 63
Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique 63
TAZ is indispensable for c-MYC-induced hepatocarcinogenesis 61
Totale 11.975
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.606
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.606
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022439 0 0 2 4 13 10 21 28 45 24 81 211
2022/20231.114 116 115 48 178 106 167 0 113 189 7 40 35
2023/2024299 52 18 5 13 83 37 2 14 0 5 29 41
2024/20253.002 26 28 175 73 152 87 208 484 1.094 450 144 81
2025/20265.153 253 1.157 1.059 728 454 263 566 144 189 213 90 37
2026/2027600 100 362 138 0 0 0 0 0 0 0 0 0
Totale 12.164